EDSA
Edesa Biotech, Inc. [EDSA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
EDSA Stock Summary
In the News
EDSA Financial details
Company Rating
-
Market Cap
14.21M
Income
-7.72M
Revenue
-1.12M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
16
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-1.63
Forward P/E
-
PEG
0.8
P/S
-
P/B
1.92
P/C
-
P/FCF
-2.26
Quick Ratio
3.29
Current Ratio
3.53
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.84
EPS next Y
-
EPS next Q
-
EPS this Y
-60%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-4.9%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
575.84%
-
-
-
-
SMA20
-
SMA50
-30.68%
SMA100
-25.64%
Inst Own
-
Inst Trans
-
ROA
-94%
ROE
-98%
ROC
-1.3%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.46-8.61
52W High
-78.25%
52W Low
-13%
RSI
42.65
Rel Volume
3.01
Avg Volume
13.5K
Volume
40.66K
Perf Week
1.16%
Perf Month
-6.95%
Perf Quarter
-13%
Perf Half Y
-6.45%
-
-
-
-
Beta
0.92
-
-
Volatility
0.03%, 0.04%
Prev Close
-1.69%
Price
1.74
Change
-2.25%
Company Profile
- Volume Average 13.5K
- Market Capitalization 14.21M
- Employee 16
- CEO Dr. Pardeep Nijhawan FRCPC, M.D.
- Headquarters Markham,ON,CA
- IPO Date 2010-06-21
-
Website
https://www.edesabiotech.com 
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
